218 related articles for article (PubMed ID: 11431013)
1. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes.
Amenta F; Bronzetti E; Cantalamessa F; El-Assouad D; Felici L; Ricci A; Tayebati SK
J Neuroimmunol; 2001 Jul; 117(1-2):133-42. PubMed ID: 11431013
[TBL] [Abstract][Full Text] [Related]
2. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra.
Hersch SM; Yi H; Heilman CJ; Edwards RH; Levey AI
J Comp Neurol; 1997 Nov; 388(2):211-27. PubMed ID: 9368838
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporters and neuronal injury.
Miller GW; Gainetdinov RR; Levey AI; Caron MG
Trends Pharmacol Sci; 1999 Oct; 20(10):424-9. PubMed ID: 10498956
[TBL] [Abstract][Full Text] [Related]
4. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
5. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
8. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
Adelbrecht C; Agid Y; Raisman-Vozari R
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
[TBL] [Abstract][Full Text] [Related]
9. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity.
Guilarte TR; Nihei MK; McGlothan JL; Howard AS
Neuroscience; 2003; 122(2):499-513. PubMed ID: 14614914
[TBL] [Abstract][Full Text] [Related]
10. Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat.
Barc S; Page G; Barrier L; Garreau L; Guilloteau D; Fauconneau B; Chalon S
J Neurochem; 2002 Feb; 80(3):365-74. PubMed ID: 11905985
[TBL] [Abstract][Full Text] [Related]
11. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter.
Jaber M; Dumartin B; Sagné C; Haycock JW; Roubert C; Giros B; Bloch B; Caron MG
Eur J Neurosci; 1999 Oct; 11(10):3499-511. PubMed ID: 10564358
[TBL] [Abstract][Full Text] [Related]
13. [Function of monoamine neurotransmitter transporters].
Sasa M
Nihon Rinsho; 2001 Aug; 59(8):1457-64. PubMed ID: 11519142
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
15. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
[TBL] [Abstract][Full Text] [Related]
16. Heptachlor alters expression and function of dopamine transporters.
Miller GW; Kirby ML; Levey AI; Bloomquist JR
Neurotoxicology; 1999 Aug; 20(4):631-7. PubMed ID: 10499361
[TBL] [Abstract][Full Text] [Related]
17. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons.
González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M
J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855
[TBL] [Abstract][Full Text] [Related]
18. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
19. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons.
Nirenberg MJ; Vaughan RA; Uhl GR; Kuhar MJ; Pickel VM
J Neurosci; 1996 Jan; 16(2):436-47. PubMed ID: 8551328
[TBL] [Abstract][Full Text] [Related]
20. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum.
Haycock JW; Becker L; Ang L; Furukawa Y; Hornykiewicz O; Kish SJ
J Neurochem; 2003 Nov; 87(3):574-85. PubMed ID: 14535941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
